Show simple item record

dc.contributor.authorVergote, I
dc.contributor.authorDean, Emma J
dc.contributor.authorLassen, U
dc.contributor.authorDe Bono, J
dc.contributor.authorDrew, Y
dc.contributor.authorMachiels, J
dc.contributor.authorNielsen, D
dc.contributor.authorArkenau, H
dc.contributor.authorForster, M
dc.contributor.authorJones, R
dc.contributor.authorSlomovitz, B
dc.contributor.authorSpicer, J
dc.contributor.authorJohnson, M
dc.contributor.authorCornez, N
dc.contributor.authorGennigens, C
dc.contributor.authorFulton, B
dc.contributor.authorLisby, S
dc.contributor.authorBasse, L
dc.contributor.authorColeman, R
dc.contributor.authorHong, D
dc.date.accessioned2017-11-22T22:08:52Z
dc.date.available2017-11-22T22:08:52Z
dc.date.issued2017
dc.identifier.citation9310 A phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.urihttp://hdl.handle.net/10541/620674
dc.title9310 A phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer.
dc.typeMeetings and Proceedingsen
dc.contributor.departmentGynaecologie-verloskunde, University Hospital Leuven, 3000 - Leuven/BEen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record